Phase 2 Data Boosts Investor Confidence
Q32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology company announced positive topline results from the 36-week Part B analysis of its SIGNAL-AA Phase 2a study evaluating bempikibart for the treatment of severe and very severe alopecia areata.
The encouraging clinical update strengthened investor optimism around the therapy’s development prospects and the company’s plans to advance the programme toward late-stage trials.
Study Achieves Primary Endpoint
The Phase 2a trial met its primary efficacy endpoint, with patients in the prespecified modified intent-to-treat (mITT) population recording a mean 35.3% reduction in Severity of Alopecia Tool (SALT) scores from baseline after 36 weeks.
The company also reported that 40.0% of patients in the mITT population achieved a SALT-20 response by Week 36, while 30.3% of all enrolled patients in the intent-to-treat analysis reached the same milestone.
Trial Included Patients with Advanced Disease
The study enrolled 33 participants with severe or very severe alopecia areata, each with baseline SALT scores ranging from 50 to 100.
More than one-third of the patients (36.4%) had previously received treatment with oral JAK inhibitors.
Participants were initially given four weekly loading doses of 200mg of bempikibart before moving to a maintenance schedule of 200mg every other week for the remaining 32 weeks of the study.
Safety Profile Remains Encouraging
Q32 Bio said bempikibart continued to demonstrate a favourable safety profile throughout the trial.
No treatment-related serious adverse events or Grade 3 or higher adverse events were reported.
The most common treatment-emergent adverse event was injection-site reactions, affecting 36.3% of patients. According to the company, these reactions were generally mild and resolved without medical intervention.
Registration Programme Planned for 2027
Following the positive Phase 2a findings, Q32 Bio intends to move bempikibart into a registration-directed clinical programme during the first half of 2027.
The company also plans to present the complete Part B dataset at a future scientific conference.
Bempikibart is a fully human anti-IL-7Rα antibody designed to restore adaptive immune function by blocking IL-7 and TSLP signalling pathways.
